Screener
Crinetics Pharmaceuticals CRNX Operating Income
Operating Income at other companies
Other financials
Where this comes from
Reported directly by Crinetics Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.
The source filing: Crinetics Pharmaceuticals’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:21 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001658247-26-000040
| Line item | Three months ended March 31, 2026 | Three months ended March 31, 2025 |
|---|---|---|
| Research and development | 100,081 | 76,240 |
| Selling, general and administrative | 50,831 | 35,526 |
| Total operating expenses | 151,112 | 111,766 |
| Loss from operations | (140,378) | (111,405) |
| Other income (expense): | ||
| Interest income | 12,664 | 14,834 |
| Other expense, net | (131) | (203) |
| Total other income, net | 12,533 | 14,631 |
Item 1. Condensed Consolidated Financial Statements (Unaudited)
FAQ
- What is Crinetics Pharmaceuticals's operating income?
- Crinetics Pharmaceuticals (CRNX) reported operating income of -$140.38M in Q1 2026.
- How has Crinetics Pharmaceuticals's operating income changed year-over-year?
- Crinetics Pharmaceuticals's operating income decreased by 26.0% year-over-year, from -$111.41M to -$140.38M.
- What is the long-term trend for Crinetics Pharmaceuticals's operating income?
- Over 4 years (2021 to 2025), Crinetics Pharmaceuticals's operating income has grown at a 48.0% compound annual growth rate (CAGR), from -$107.7M to -$516.77M.
- What does operating income mean?
- Gross profit minus all operating expenses (SG&A, R&D, D&A). Measures the profit from core business operations before interest, taxes, and non-operating items.
Ask your AI about Crinetics Pharmaceuticals's operating income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude